# Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b

> **NCT03485846** · PHASE2 · COMPLETED · sponsor: **R-Pharm** · enrollment: 105 (actual)

## Conditions studied

- Chronic Hepatitis C Genotype 1b

## Interventions

- **DRUG:** Narlaprevir
- **DRUG:** Ritonavir
- **DRUG:** Daclatasvir

## Key facts

- **NCT ID:** NCT03485846
- **Lead sponsor:** R-Pharm
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2018-08-29
- **Final completion:** 2018-11-21
- **Target enrollment:** 105 (ACTUAL)
- **Last updated:** 2018-12-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485846

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485846, "Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03485846. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*